Biopharmx (BPMX) Stock Price, News & Analysis

Company Overview

BiopharmX Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative topical and transmucosal therapies for dermatological and oral mucosal conditions. Headquartered in Princeton, New Jersey, the company applies proprietary formulations to address unmet needs in areas such as cutaneous warts, oral mucositis, herpes labialis and psoriasis. In addition to its prescription pipeline, BiopharmX markets OTC skincare products that include moisturizing creams, acne treatments and sun care formulations.

The company’s lead product candidates include BPX-01, a mucoadhesive topical treatment for the prevention of oral mucositis in cancer patients; BPX-04, a topical gel for the treatment of cold sores (herpes labialis); BPX-07, a user-applied therapy for cutaneous warts; and BPX-02, a topical foam for mild-to-moderate plaque psoriasis. Several of these assets have completed Phase 2 clinical studies, and the company is pursuing regulatory interactions aimed at advancing pivotal trials and potential commercialization partnerships.

BiopharmX’s research and development efforts leverage in-house formulation expertise alongside third-party manufacturing and clinical trial networks in the United States. Management has positioned the company to enter strategic alliances for broader geographic rollout upon regulatory approval, with a focus on markets that demonstrate high unmet need for non-systemic dermatological therapies. By combining a diversified product portfolio with a streamlined development model, BiopharmX aims to deliver differentiated treatments to patients and long-term value to shareholders.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 336,508 shs
• Average Volume: 2.15 million shs
• Market Capitalization: $111.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BPMX Stock Analysis - Frequently Asked Questions

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) released its quarterly earnings data on Tuesday, December, 10th. The biotechnology company reported ($1.68) EPS for the quarter, beating the consensus estimate of ($2.64) by $0.96.

When did Biopharmx's stock split?

Biopharmx's stock reverse split on the morning of Tuesday, May 19th 2020.The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Biopharmx?

Shares of BPMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biopharmx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Hawkins (HWKN), Novavax (NVAX) and Protalix BioTherapeutics (PLX).

Company Calendar

• Last Earnings: 12/10/2019
• Today: 5/07/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:BPMX
• Previous Symbol: NYSE:BPMX
• CIK: N/A
• Web: www.biopharmx.com
• Phone: +1-650-8895020
• Fax: N/A
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,278,000
• Free Float: N/A
• Market Cap: $111.86 million
• Optionable: Not Optionable
• Beta: N/A